1、Conditioning regimens were BU/CY of AML and CML, or TBI/CY of ALL.
急性髓細(xì)胞白血病和慢性粒細(xì)胞白血病患者采用BU/CY方案:馬利蘭4mg/(kg·d)×4d,環(huán)磷酰胺60mg/(kg·d)×2d; 急性淋巴細(xì)胞白血病患者預(yù)處理采用TBI/CY方案:全身照射5.0Gy/d×2d,環(huán)磷酰胺60mg/(kg·d)×2d。

2、A NEW TCR DELTA GENE REARKANGEMENT IN ACASE OF AML AND ITS ANALYSIS METHOD
一例AML中一種新的TCRδ基因重排及其分析方法

3、Clinical Practice Guidelines and Commentary on AML of American NCCN
美國(guó)NCCN的急性髓性白血病(AML)診療指南及評(píng)述

4、Clinical Observations of 15 Cases With AML Treated Hardly by DA and Vm 26
DA加V_M26方案治療難治性急性髓細(xì)胞性白血病15例臨床觀察

5、IN VITRO TREATMENT OF AML CELLS WITH LYSOSOMOTROPIC AGENT IHW_2 AND IHW_3
親溶酶體藥物IHW_2和IHW_3對(duì)急性髓細(xì)胞白血病細(xì)胞體外凈化的研究

6、Expression of P170 in Elder AML and Its Correlation with Prognosis
老年急性髓系白血病P170的表達(dá)與預(yù)后關(guān)系的研究

7、RT-PCR detection of bcl-2 expression in AML and its clinical significance
RT-PCR檢測(cè)bcl-2在急性髓細(xì)胞白血病的表達(dá)及其臨床意義

8、The goal of treatment for AML is to cure the disease.
急性粒細(xì)胞性白血病（AML）治療的目標(biāo)是治愈疾病。

9、Study of antitumor activities of myeloid LAK cells from AML in vitro.
AML骨髓LAK細(xì)胞抗腫瘤活性的體外研究

10、Objective to study the factors that affect the recent curative effect on AML with t.
目的研究影響伴t(8； 21)急性髓系白血病(aml)近期療效的因素。

11、Business Goal - Transition all systems to use the new AML process over the next year.
業(yè)務(wù)戰(zhàn)略目標(biāo)——明年把所有系統(tǒng)轉(zhuǎn)換為使用新的AML過程。

12、EFFECT OF HUMAN RECOMBINANT G-CSF, EPO ON MARROW CELLS IN AML AND MDS
重組人G-CSF、EPO對(duì)白血病及骨髓增生異常綜合征細(xì)胞的作用

13、The structure and mRNA expression of p16 gene in AML cells
急性髓系白血病細(xì)胞p16基因結(jié)構(gòu)及轉(zhuǎn)錄水平表達(dá)

14、DR5 may play an important role in TRAIL-inducing apoptosis of AML cells.
DR5在TRAIL介導(dǎo)的急性髓系白血病細(xì)胞凋亡中起重要的作用。

AML翻譯

【計(jì)】 先進(jìn)數(shù)學(xué)庫(kù), 應(yīng)用模塊庫(kù), 陣列機(jī)語(yǔ)言, 匯編微程序庫(kù) 詳情